Metformin Hydrochloride Extended Release Tablets

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and can reduce HbAlc by 1% to 2%. Its mechanism of lowering blood sugar is: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization. 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc. 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output. 4. Inhibit intestinal wall cells from taking up glucose. Unlike the action of insulin, this product does not promote fat synthesis, has no obvious hypoglycemic effect on normal people, and generally does not cause hypoglycemia when used alone for type 2 diabetes. <b

The main ingredient of this product is metformin hydrochloride, and its chemical name is 1,1-dimethylbiguanide hydrochloride.

This product is a film-coated tablet, which appears off-white or white after removing the coating.

It is suitable for patients with type 2 diabetes who cannot be well controlled by diet and exercise alone. This product can be used alone or in combination with sulfonylureas or insulin.

Oral administration, during or after meals. The initial dosage is usually once a day, 1 tablet (500 mg) at a time, taken at dinner, and the dosage is adjusted according to blood sugar and urine sugar. The maximum daily dose does not exceed 4 tablets (2000 mg). If once a day, 4 tablets (2000 mg) each time cannot achieve satisfactory therapeutic effects, it can be changed to twice a day, 2 tablets (1000 mg) each time.

Some patients experience gastrointestinal discomfort after taking this product orally, such as nausea, vomiting, abdominal pain, diarrhea, constipation, bloating, indigestion, heartburn, as well as dizziness, headache, flu-like symptoms, abnormal taste, muscle pain, hypotension, palpitations, flushing, chills, chest discomfort, rash, weakness, tiredness, etc.

This product is contraindicated in patients with type 2 diabetes accompanied by ketoacidosis, liver and kidney dysfunction, heart failure, acute myocardial infarction, severe infection and trauma, major surgery, clinical hypotension and hypoxia, a history of lactic acidosis, and those who are allergic to this product.

Precautions for children: The clinical safety and efficacy of this product in children have not been confirmed. Precautions for pregnancy and lactation: There have been no adequate and strictly controlled clinical studies in pregnant women, and the efficacy and safety of this product in pregnant women are still unclear, so pregnant women are prohibited from using this product. Metformin can be excreted through breast milk, so it is prohibited for lactating women to use this product. Precautions for the elderly: Elderly patients will experience physiological decline in renal function with age, so it is necessary to pay attention to the choice of dosage and regular examination of renal function. Elderly patients should generally not receive the maximum dose of this product. Elderly patients over 80 years old should not use this product unless their creatinine clearance rate shows that their renal function has not decreased.

1. When used in combination with insulin, the hypoglycemic effect is enhanced, and the dosage should be adjusted. 2. This product can enhance the anticoagulant effect of anticoagulants (such as warfarin, etc.), which may cause bleeding tendency. 3. Cimetidine can increase the bioavailability of this product and reduce the renal clearance rate, so the dosage of this product should be reduced. 4. Furosemide increases the serum and whole blood drug concentrations of metformin, but does not change the renal clearance rate of metformin. 5. Nifedipine can increase the absorption of metformin and increase the excretion in urine, but does not affect Tmax and half-life.

Store in a sealed, dry place. The validity period is tentatively 12 months.

0.5g

24 months.

Hainan Poly Pharm. Co., Ltd.

• Founded in:

  1992-07-14

• Address:

  Guilinyang Economic Development Zone, Meilan District, Haikou City

• Tax NO.:

  91460000620000247L

• Registered Funds:

  448.350021 million yuan

• Website:

  Log in to view

• Email:

  Log in to view